Active, not recruitingPhase 1NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nuvectis Pharma, Inc.
- Principal Investigator
- Udai Banerji, ProfInstitute of Cancer Research, Royal Marsden Foundation Trust
- Intervention
- NXP800(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (22)
- Honor Health, Phoenix, Arizona, United States
- UC San Diego Health - Moores Cancer Center, La Jolla, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Yale Gynecologic Oncology, New Haven, Connecticut, United States
- Florida Cancer Specialists South, Fort Myers, Florida, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Florida Cancer Specialists Research North, St. Petersburg, Florida, United States
- Florida Cancer Specialists Research East, West Palm Beach, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Women's Cancer Care Associates, Albany, New York, United States
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States
- Oncology Associates of Oregon, Eugene, Oregon, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
Gynecologic Oncology Group Foundation · The European Network for Gynaecological Oncological Trial groups (ENGOT)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05226507 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerElizabeth K. Lee MD
- ACTIVE NOT RECRUITINGPHASE2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.
- RECRUITINGPHASE1, PHASE2NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)